ICON has launched cytometry services from its Central Laboratories business unit to support the testing requirements and development phase ofcompounds. Global flow cytometry services will be offered from ICON Central Labs in New York, Dublin, Bangalore and Singapore.

ICON Cytometry Services allow clients to collaborate with ICON at the early stages of development to create compound-specific assays and to work with ICON Central Labs’ R&D team to develop flow cytometry methodology, customized SOPs and other special requirements, including reporting. The customized flow cytometry panels can then be used throughout the compound development. Clients will also be able to choose from a wide range of validated assays, often suited to large-scale, high-volume requirements of later phase global trials.

Tom O’Leary, president, ICON Central Laboratories, said, “Flow Cytometry has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialized testing. Our new Cytometry Services offering provides clients with a better range of options, all of which are supported by a team of highly experienced scientists, robust instrumentation and rigorous quality control systems.”